Solasia
Pioneering Patient-Centered Oncology in the Asia-Pacific

The healthcare industry is experiencing a shift driven by rapid technological advances. Particularly in oncology, the trend has significantly moved towards patient-centered care models focused on personalized treatment plans, comfort, and overall quality of life.

Solasia Pharma K.K. stands out in the industry by going beyond potent treatments and providing holistic patient care. Its approach considers the physical and psychological aspects of cancer treatment and acknowledges that cancer still poses a significant challenge for healthcare systems worldwide.

The Japanese biopharmaceutical firm pioneers innovative oncology solutions tailored to the needs of the Asia-Pacific region. Its mission is to introduce groundbreaking cancer therapies, ensure they come with minimal burden on patient’s health, and align with the industry-wide push towards comprehensive patient care.

“The commitment to patient support starts from the ground up, from our meticulous development process to our strategic hiring policies. We hand-pick professionals who have polished their skills in global pharmaceutical firms, ensuring our lean yet effective development team is fully equipped with the necessary knowledge and skills to bring our cutting-edge products to life,” says Yoshihiro Arai, president, and CEO.

The distinct product portfolio features three novel offerings, each designed to improve patient comfort and treatment efficacy and embody a patient-first ethos. First among these offerings is Sancuso^®, an extended-release transdermal system patch that administers Granisetron into the patient’s bloodstream over several days. Sancuso^® is the world’s first and only transdermal patch of a 5-hydroxytryptamine sub-type 3 (5-HT3) receptor antagonist and is used for the prevention of chemotherapy-induced nausea and vomiting (CINV), which can lead to severe medical complications like dehydration, malnutrition, and even aspiration pneumonia.

CINV could occur with a high percentage of patients on high-dose chemotherapy regimens. Providing relief for up to seven days, Sancuso^® reduces the need for frequent hospital visits and significantly improves the overall comfort of chemotherapy patients.

Next in Solasia’s lineup is episil^®, an original medical device designed to manage pain caused by chemotherapy and radiotherapy-induced oral lesions, including mucositis and stomatitis. Episil was developed using Camurus’ award-winning patented technology, FluidCrystal technology.

Episil^® forms a protective film on the oral mucosa upon contact, providing immediate pain relief. This physical barrier greatly enhances patient comfort, making it an invaluable aid for those suffering from these painful oral conditions.

The capstone of Solasia’s product line is DARVIAS, a cutting-edge treatment recently approved by the Japanese regulatory authority. DARVIAS may provide a new mode of treatment option for various hematologic and solid tumors. It disrupts mitochondrial function, increases reactive oxygen species, and modulates intracellular signal transduction pathways, thereby inducing cell cycle arrest and apoptosis. DARVIAS has the potential to provide patients with anti-tumor effects with fewer side effects, as demonstrated in clinical trials.

SP-04, currently in the preclinical development stage, is also part of Solasia’s product portfolio. SP-04 is a superoxide dismutase mimetic to discompose and removes superoxide as one of the reactive oxygen substances (ROS). ROS is a major cause to develop peripheral neuropathy often shown with high incidence in the treatment of some kinds of chemotherapy. There is no approved medicine to directly treat peripheral neuropathy yet and high medical needs are expected in this field.

Integral to Solasia’s strategy is its nimble and low-hierarchical structure, which facilitates rapid decision-making and product development by a small team of elite. It is maximized to rely on external collaborations with advisors and consultants to bolster expertise and accelerate program delivery.

Solasia’s approach extends beyond product development. It actively engages in global studies to broaden patient populations, shorten development timelines, and reduce costs. It is keen on exploring opportunities beyond Asian countries, reflecting its promise to diversify patient populations and provide effective treatments worldwide.

Its perspective on patient care in oncology indicates a forward-thinking healthcare model. Merging advanced therapies and patient well-being redefines the cancer treatment narrative. Solasia’s devotion to improving patient outcomes encompasses the aspiration to supply a balanced care experience that puts patients at the heart of every decision.